News Abbott Laboratories

Stocks

ABT

US0028241000

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 16:02:23 2026-11-13 EST			5-day change	1st Jan Change
108.52 ^USD	+1.18%		-1.28%	-13.38%

11-12	Tandem Diabetes Care Gets Health Canada Approval for Expanded t:slim X2 Use	MT
11-10	Abbott Announces Availability Of Panbio COVID-19/Flu A&B Self-Test	CI

All News

Mentions Relevance

648da1aee7051.jJAonAVerOPH5IwRlQqZpuoP0mZBzF7WyW8eYw7QTQM.uqNZ72ENzqSfo_Zo3WDzydJFggwunziCrV4tUFafKkfG_mHSaTTp1KSutA

11-10	Abbott Announces Availability Of Panbio COVID-19/Flu A&B Self-Test	CI
11-10	Abbott Laboratories : Receives FDA Approval and CE Mark for Implantable Cardioverter-Defibrillator Lead Designed to Work with the Heart's Natural Electrical System	PU
11-10	BofA Adjusts Price Target on Abbott Laboratories to $125 From $115	MT
11-06	Abbott Laboratories Insider Sold Shares Worth $406,000, According to a Recent SEC Filing	MT
11-02	Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke	PR
11-02	Abbott Announces One-Year Results for Amulet 360 Left Atrial Appendage Occluder from Veritas Study	CI
11-02	HSS Medical Supply Announces Distributor Agreement with Abbott for ID NOW Rapid Molecular Testing Platform	CI
11-02	Abbott Says SonicForce Device Trial Meets Primary Safety, Effectiveness Endpoints	MT
11-01	Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System	PR
11-01	Abbott Reports Strong 30-Day Results From TECTONIC CAD IVL IDE Study Evaluating Investigational SonicForce Coronary Intravascular Lithotripsy System	CI
10-30	Abbott Recalls Amplatzer Amulet Left Atrial Appendage Occluder	CI
10-29	Abbott Laboratories Starts Trial for Device to Treat Mitral Heart Valve Disease	MT
10-29	Abbott Initiates Pivotal Trial for Cephea Mitral Valve System	CI
10-29	Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease	PR
10-28	Abbott Laboratories : receives FDA approval for first and only device in the U.S. to treat leaks after heart valve replacement without additional surgery	PU
10-27	Abbott Receives FDA Approval For Amplatzer Paraclose PVL Occluder	CI
10-27	Abbott Laboratories Shares Fall After Argus Downgrade	MT
10-27	Argus Downgrades Abbott Laboratories to Hold From Buy	MT
10-26	Abbott Laboratories Launches Oncodetect Molecular Residual Disease Test	MT
10-26	Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment	PR
10-26	Abbott Launches Whole-Genome Sequencing Oncodetect Molecular Residual Disease Test To Detect Traces Of Cancer During And After Treatment	CI
10-23	Abbott Presents New Esmo Data Showing 30-Percent Absolute Improvement in Sensitivity with the Whole-Genome Sequencing Oncodetect Test in Colorectal Cancer	CI
10-23	Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer	PR
10-22	Abbott Laboratories' Q3 Somewhat a 'Mixed Bag' With Softened Outlook, Nutrition Spinoff, Oppenheimer Says	MT
10-22	Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says	MT